6-ethyl-2-aminopicoline | 83004-19-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 6-ethyl-2-aminopicoline
• 英文别名: 2-Pyridinemethanamine, 6-ethyl-；(6-ethylpyridin-2-yl)methanamine
• CAS: 83004-19-7
• 化学式: C₈H₁₂N₂
• mdl: MFCD18256490
• 分子量: 136.197
• InChiKey: HEEVDXLREYYFOO-UHFFFAOYSA-N

物化性质

• 沸点：
  65 °C(Press: 1 Torr)
• 密度：
  1.005±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.375
• 拓扑面积：
  38.9
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  聚合甲醛 、 6-ethyl-2-aminopicoline 在 甲酸 作用下， 以1.5 g的产率得到6-ethyl-2-dimethylaminopicoline
  参考文献：
  名称：

  Pratesi; Villa; Ferri, Farmaco, Edizione Scientifica, 1982, vol. 37, # 6, p. 398 - 410

  摘要：

  DOI：
• 作为产物：
  描述：

  6-乙基皮考啉腈 在 lithium aluminium tetrahydride 作用下， 以 乙醚 为溶剂， 以2 g的产率得到6-ethyl-2-aminopicoline
  参考文献：
  名称：

  Pratesi; Villa; Ferri, Farmaco, Edizione Scientifica, 1982, vol. 37, # 6, p. 398 - 410

  摘要：

  DOI：

文献信息

• [EN] AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS<br/>[FR] AZOLOPYRIMIDINE POUR LE TRAITEMENT DE TROUBLES LIÉS AU CANCER
  申请人：ARCUS BIOSCIENCES INC

  公开号：WO2018136700A1

  公开（公告）日：2018-07-26

  Compound that is an inhibitor of at least one of the A2A and A2B adenosine receptors, and compositions containing the compound and methods for synthesizing the compound, are described herein. The use of such compound and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by the adenosine A2A receptor and/or the adenosine A2B receptor.

  本文描述了一种至少抑制A2A和A2B腺苷受体中至少一种的化合物，以及含有该化合物的组合物和合成该化合物的方法。利用这种化合物和组合物治疗各种疾病、紊乱和病况，包括至少部分由腺苷A2A受体和/或腺苷A2B受体介导的癌症和免疫相关紊乱。
• [EN] DIAMINOPYRAZOLO[1,5-A]PYRIMIDINE-6-CARBONITRILE COMPOUNDS AS ADENOSINE 2A RECEPTOR AND ADENOSINE 2B RECEPTOR ANTAGONIST<br/>[FR] COMPOSÉS DIAMINOPYRAZOLO [1,5-A] PYRIMIDINE-6-CARBONITRILE UTILISÉS COMME ANTAGONISTE DU RÉCEPTEUR DE L'ADÉNOSINE 2A ET DE L'ADÉNOSINE 2B
  申请人：BUGWORKS RES INDIA PVT LTD

  公开号：WO2022149167A1

  公开（公告）日：2022-07-14

  The present disclosure provides a compound of Formula I or its pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, stereoisomers, racemates, pharmaceutically active derivatives thereof. The compounds of Formula I act as antagonists to adenosine receptors. The present disclosure also provides a process for preparation of compounds of Formula I and pharmaceutical composition thereof.

  本公开提供I式化合物或其药学上可接受的盐、络合物、水合物、溶剂物、互变异构体、多晶形、立体异构体、混合物及其药学上活性衍生物。I式化合物作为腺苷受体的拮抗剂。本公开还提供一种制备I式化合物及其药物组合物的方法。
• PRATESI, P.;VILLA, L.;FERRI, V.;DE, MICHELI, C.;GRANA, E.;SANTAGOSTINO, B+, FARMACO. ED. SCI., 1982, 37, N 6, 398-410
  作者：PRATESI, P.、VILLA, L.、FERRI, V.、DE, MICHELI, C.、GRANA, E.、SANTAGOSTINO, B+

  DOI：——

  日期：——
• CHIRAL SPIRO-PYRIDYLAMIDOPHOSPHINE LIGAND COMPOUND, SYNTHESIS METHOD THEREFOR AND APPLICATION THEREOF
  申请人：Zhou Qilin

  公开号：US20130225822A1

  公开（公告）日：2013-08-29

  The present invention relates to a chiral spiro-pyridylamidophosphine ligand compound, synthesis method therefor and application thereof. The chiral spiro-pyridylamidophosphine compound is a compound having a structure of Formula (I), a racemate or optical isomer thereof, or a catalytically acceptable salt thereof, and is mainly characterized by having a chiral spiro-dihydro-indene skeleton in its structure. The chiral spiro-pyridylamidophosphine compound may be synthesized with optical active 7-diaryl/alkylphosphino-7′-amino-1,1′-spiro-dihydro-indene or substituted 7-diaryl/alkylphosphino-7′-amino-1,1′-spiro-dihydro-indene having a spiro-skeleton as chiral starting material. The chiral spiro-pyridylamidophosphine compound may be used as a chiral ligand in asymmetric hydrogenation of a carbonyl compound catalyzed by iridium, in which the reaction activity is very high, the amount of the catalyst may be 0.0001 mol %, and the enantioselectivity of the reaction is up to 99.9% ee.
• US8962839B2
  申请人：——

  公开号：US8962839B2

  公开（公告）日：2015-02-24